New warfarin competitors: heartwire collection

New warfarin competitors

For six decades, warfarin cemented its reputation as the world's most effective anticoagulant--and the most troublesome to dose appropriately. In recent years, a host of new agents have been vying to be the long-sought-after alternative to warfarin by posing fewer risks and doing away with the need for regular INR monitoring.

Search for

Sort by

Page

Showing 1 - 25 of 49 documents.

Arrhythmia/EP

New anticoagulants beat warfarin in AF meta-analysis

3 COMMENTS - Oct 18, 2012 17:00 EDT

The benefits of the new wave of anticoagulants for atrial-fibrillation patients are supported by a major meta-analysis of studies comparing the new drugs with warfarin.

Thrombosis

Role reversal: Hematologists advise on bleeding with newer anticoagulants

Jun 21, 2012 15:00 EDT

New laboratory data using human blood shed more light on the use of coagulation factors to reverse bleeding with newer anticoagulants; an online AHA presentation of the results yesterday led to much discussion on this issue among cardiologists and hematologists.

Medscape Medical News

Label update for dabigatran

Jun 7, 2012 10:45 EDT

Boehringer Ingelheim announced the label will now reflect the 150-mg twice-daily dose was "superior" to warfarin to prevent ischemic and hemorrhagic stroke in nonvalvular atrial fibrillation.

Thrombosis

XAMOS: Rivaroxaban in real-world orthopedic prophylaxis

Apr 19, 2012 13:45 EDT

The trial is said to confirm the benefits shown in the RECORD phase 3 trial program.

Thrombosis

Oral anticoagulants in the real world: Bleeding rates and medical costs compared

Apr 2, 2012 11:45 EDT

Two separate experiences with dabigatran from different US centers showing very different results, and new cost-effectiveness analyses with the new drugs were reported in a poster session at last week's ACC meeting.

Arrhythmia/EP

Rivaroxaban gets NICE nod in UK for AF

Apr 2, 2012 09:30 EDT

In its final draft guidance, the UK National Institute for Clinical Excellence has recommended rivaroxaban as an option for the prevention of stroke and systemic embolism in people with atrial fibrillation.

Thrombosis

FDA moves on rivaroxaban and apixaban

Mar 1, 2012 10:00 EST

UPDATED // The FDA has granted priority review to rivaroxaban for the additional indication of ACS, meaning a decision will be made within six months of the filing of this application rather than 10. The agency has also extended the review time for apixaban for prevention of stroke in atrial fibrillation by three months, because of additional clinical information submitted by the manufacturers.

Medscape Medical News

Rocket-AF: Predictors of ICH include warfarin treatment

Feb 23, 2012 10:15 EST

A new subanalysis identifies risk factors for bleeding in ROCKET-AF and finds treatment with warfarin vs rivaroxaban was one of these.

Medscape Medical News

Apixaban superior for AF patients with previous stroke, TIA

Feb 9, 2012 11:15 EST

Substudies of the ARISTOTLE and AVERROES trials find apixaban is safe and effective for patients with previous events vs warfarin and aspirin respectively.

The Cardiology Show

AHA 2011 trials to treatments: ATLAS ACS2, TRACER, and MI FREEE

3 COMMENTS - Nov 16, 2011 14:30 EST

Dr Valentin Fuster sits down with Drs William Boden, John Chapman, Keith Fox, Anne Gillis, Jessica Mega, and Clyde Yancy to tackle the brave new world of antithrombotics and to ask whether academics have left the real world, and their patients, behind.

Arrhythmia/EP

Public Citizen urges FDA not to approve rivaroxaban for use in AF

4 COMMENTS - Oct 21, 2011 11:15 EDT

The US consumer group says there are several areas of uncertainty in the ROCKET-AF trial that raise questions as to whether rivaroxaban is as safe and effective as warfarin and asserts that the new indication should not be approved until further studies have been conducted to address these issues.

Editorial series

Novel anticoagulants in AF: A guide for the clinical practitioner

2 COMMENTS - Sep 15, 2011 10:47 EDT

Join Drs Samuel Goldhaber, Jean-Pierre Bassand, Stavros Konstantinides, and Alexander GG Turpie as they guide the clinical practitioner through the landscape of novel anticoagulants in AF.

Editorial series

ESC 2011 research highlights: A slideshow presentation

Sep 7, 2011 12:22 EDT

View our slideshow for a summary of top trials and presentations from The European Society of Cardiology (ESC) 2011 Congress.

Arrhythmia/EP

FDA will argue against rivaroxaban approval for AF indication

1 COMMENT - Sep 7, 2011 11:30 EDT

UPDATED WITH COMMENTARY // In the FDA briefing documents for the committee, which were posted online Tuesday, the clinical review recommends that a complete response letter be issued and that the drug's sponsor conduct additional studies before the FDA approves the latest anticoagulant on the scene for stroke prevention in atrial fibrillation.

The Cardiology Show

The Paris review: ARISTOTLE, dal-VESSEL, and PURE at ESC 2011

4 COMMENTS - Aug 31, 2011 09:54 EDT

Share the excitement from the blockbuster ESC 2011 Congress with Drs Valentin Fuster, Mariell Jessup, Adnan Kastrati, Magnus Ohman, Terje Pedersen, Silvia Priori, and Bryan Williams.

ROCKET-AF lands in <i>NEJM</i>: Rivaroxaban noninferior to warfarin in AF patients

Arrhythmia/EP

ROCKET-AF lands in NEJM: Rivaroxaban noninferior to warfarin in AF patients

1 COMMENT - Aug 10, 2011 17:00 EDT

With ROCKET-AF meeting its primary end point and now being published in the New England Journal of Medicine, the next step for the new oral anticoagulant will be the FDA advisory panel review in September.

Acute Coronary Syndromes

APPRAISE-2: Apixaban risks outweigh benefits in high-risk ACS

1 COMMENT - Jul 24, 2011 19:00 EDT

One investigator says the idea of adding anticoagulants to antiplatelet therapy following acute coronary syndrome is likely "just not a good idea in your run-of-the-mill post-ACS patients."

Arrhythmia/EP

Do the ESC AF anticoagulation guidelines need an update already?

Jul 8, 2011 16:45 EDT

CORRECTED // When the ESC was planning new guidelines on the treatment of atrial fibrillation, the task force expected to be able to include information on trials of many new anticoagulants that were about to come on the market. But only a few of these expected trials were complete when guidelines were published in September 2010, so the ESC is considering another update.

Thrombosis

FDA approves oral anticoagulant rivaroxaban for DVT prevention at surgery

2 COMMENTS - Jul 1, 2011 18:00 EDT

Approval of the once-daily oral factor Xa inhibitor, based on the RECORD trials, has been long awaited.

Medscape Medical News

Time to revisit dabigatran dose in the US?

6 COMMENTS - May 31, 2011 15:00 EDT

Researchers say new bleeding-risk data from the RE-LY trial suggest that the 110-mg dose may be best for patients older than 75 years and provide a rationale for the FDA to revisit this issue.

Thrombosis

Apixaban clears EU hurdle for VTE prevention

1 COMMENT - Mar 18, 2011 12:30 EDT

A new factor Xa inhibitor, apixaban, has cleared the penultimate hurdle on the road to EU approval for the prevention of venous thromboembolism in patients undergoing elective hip- or knee-replacement surgery.

Features

Experts compare new oral anticoagulants preparing to battle for the warfarin market

22 COMMENTS - Dec 14, 2010 16:30 EST

It seems likely that there will be two new oral anticoagulants available in the not-too-distant future that can be used as an alternative to warfarin in the prevention of stroke in AF patients. But how do the two new agents compare with each other, and what about other possible indications and the host of other similar agents in development?

Thrombosis

Edoxaban gunning for AF, treatment of VTE

Dec 10, 2010 15:00 EST

CORRECTED // The investigational factor Xa inhibitor edoxaban will not be developed for the prevention of VTE in the US and EU; rather, the company is concentrating its efforts on AF and treatment of VTE. For these indications, edoxaban will be racing another factor Xa inhibitor, apixaban, to market.

Thrombosis

ADVANCE analysis: Apixaban effective, safe, for VTE prevention following hip/knee surgery

Dec 7, 2010 09:30 EST

The absolute reduction in VTE risk was 0.76%, meaning that for every 125 patients treated with apixaban instead of enoxaparin, clinicians would prevent one episode of major VTE, report investigators.

Acute Coronary Syndromes

Apixaban bleeding risks prompt Pfizer/Bristol-Myers Squibb to halt APPRAISE-2 ACS trial

5 COMMENTS - Nov 19, 2010 11:50 EST

In a week when new factor-Xa inhibitors have dominated the news, the announcement that yet another agent in this class has run into trouble will raise questions about ACS trials for its competitors.

Search for

Sort by

Page

Showing 1 - 25 of 49 documents.